Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®

Saint-Herblain (France), November 10, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the...

Related Keywords

Pan American Health Organization ,District Of Columbia ,United States ,New York ,Brazil ,France ,Washington ,Japan ,Itaparica ,Estado De Pernambuco ,Canada ,Paix ,Haute Normandie ,Japanese ,Americans ,Richard Hatchett ,Thomas Lingelbach ,Joshua Drumm ,Instituto Butantan ,Juan Carlos Jaramillo ,Health Canada ,Advisory Committee On Immunization Practices ,Vp Global Communications European Investor Relations ,Drug Administration ,Coalition For Epidemic Preparedness Innovations ,Pfizer ,Oxford University ,Oxford University Press ,Health Information For International ,Centers For Disease ,Pan American Health Organization World ,European Medicines Agency ,Euronext Paris ,Priority Review Voucher ,Advisory Committee ,Immunization Practices ,Chief Executive Officer ,Epidemic Preparedness Innovations ,Chief Medical Officer ,Middle Income Countries ,Southeast Asia ,Prescribing Information ,Successfully Completes Pivotal Phase ,Single Shot Chikungunya Vaccine ,Reports Positive ,Month Antibody Persistence Data ,Medication Guide ,Enterotoxigenic Escherichia ,Trop Dis ,Royal Society ,Tropical Medicine ,American Health Organization ,World Health ,Epidemiological Alert ,Nat Immunol ,Announces Initiation ,Adolescent Phase ,Single Shot Chikungunya Vaccine Candidate ,Instituto Butantan Sign Final Agreement ,Middle Income ,Submits Chikungunya Vaccine Marketing Application ,Health Information ,International Travel ,Disease Control ,Zine Analytics Chikungunya ,Cumulative Cases ,